Compile Data Set for Download or QSAR
Report error Found 30 Enz. Inhib. hit(s) with all data for entry = 1346
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317564(2-(((3R,6R)-1-(2-(2H-1,2,3-Triazol-2-yl)benzoyl)-6...)
Affinity DataIC50: 7nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317565(3-methyl-2-{[(3R,6R)- 6-methyl-1-{[2-(2H- tetrazol...)
Affinity DataIC50: 7nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317562(2-(((3R,6R)-1-(2-(2H-Tetrazol-2-yl)benzoyl)-6-meth...)
Affinity DataIC50: 9nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317566(2-((3R,6R)-1-(2-(2H-1,2,3-Triazol-2-yl)thiophene-3...)
Affinity DataIC50: 11nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317561(3-methoxy-2-{[(3R,6R)-6- methyl-1-{[2-(2H-1,2,3- t...)
Affinity DataIC50: 11nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317574(2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-triazol-2- y...)
Affinity DataIC50: 13nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317568(2-(((3R,6R)-1-(2-(2H-1,2,3-Triazol-2-yl)benzoyl)-6...)
Affinity DataIC50: 20nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317572(2-{ethyl[(3R,6R)-6- methyl-1-{[2-(2H-1,2,3- triazo...)
Affinity DataIC50: 23nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317573(2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-triazol-2- y...)
Affinity DataIC50: 23nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317559(2-(((3R,6R)-1-(2-(2H-1,2,3-Triazol-2-yl)benzoyl)-6...)
Affinity DataIC50: 29nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317569(2-{methyl[(3R,6R)-6- methyl-1-{[2-(2H- tetrazol-2-...)
Affinity DataIC50: 32nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317571(3-methoxy-2- (methyl{(3R,6R)-6- methyl-1-[(2-pyrim...)
Affinity DataIC50: 34nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317570(3-methoxy-2- {methyl[(3R,6R)-6- methyl-1-{[2-(2H-1...)
Affinity DataIC50: 39nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317567(3-methoxy-2-((3R,6R)-6- methyl-1-(2-(pyrimidin-2- ...)
Affinity DataIC50: 47nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317561(3-methoxy-2-{[(3R,6R)-6- methyl-1-{[2-(2H-1,2,3- t...)
Affinity DataIC50: 267nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317574(2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-triazol-2- y...)
Affinity DataIC50: 330nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317567(3-methoxy-2-((3R,6R)-6- methyl-1-(2-(pyrimidin-2- ...)
Affinity DataIC50: 384nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317564(2-(((3R,6R)-1-(2-(2H-1,2,3-Triazol-2-yl)benzoyl)-6...)
Affinity DataIC50: 745nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317566(2-((3R,6R)-1-(2-(2H-1,2,3-Triazol-2-yl)thiophene-3...)
Affinity DataIC50: 827nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317565(3-methyl-2-{[(3R,6R)- 6-methyl-1-{[2-(2H- tetrazol...)
Affinity DataIC50: 1.15E+3nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317559(2-(((3R,6R)-1-(2-(2H-1,2,3-Triazol-2-yl)benzoyl)-6...)
Affinity DataIC50: 1.74E+3nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317575(N-((3R,6R)-1-(2-(2H-1,2,3-Triazol-2-yl)benzoyl)-6-...)
Affinity DataIC50: 1.78E+3nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317562(2-(((3R,6R)-1-(2-(2H-Tetrazol-2-yl)benzoyl)-6-meth...)
Affinity DataIC50: 1.92E+3nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317572(2-{ethyl[(3R,6R)-6- methyl-1-{[2-(2H-1,2,3- triazo...)
Affinity DataIC50: 1.99E+3nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317568(2-(((3R,6R)-1-(2-(2H-1,2,3-Triazol-2-yl)benzoyl)-6...)
Affinity DataIC50: 2.05E+3nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317569(2-{methyl[(3R,6R)-6- methyl-1-{[2-(2H- tetrazol-2-...)
Affinity DataIC50: 2.24E+3nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317573(2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-triazol-2- y...)
Affinity DataIC50: 2.55E+3nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317575(N-((3R,6R)-1-(2-(2H-1,2,3-Triazol-2-yl)benzoyl)-6-...)
Affinity DataIC50: 1.00E+4nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317570(3-methoxy-2- {methyl[(3R,6R)-6- methyl-1-{[2-(2H-1...)
Affinity DataIC50: 1.00E+4nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM317571(3-methoxy-2- (methyl{(3R,6R)-6- methyl-1-[(2-pyrim...)
Affinity DataIC50: 1.00E+4nMAssay Description:FLIPR Ca2+ Flux Assay- (Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001). In a typical experiment the OX1 and OX2 receptor antagonisti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent